Activating mutations in ALK provide a therapeutic target in neuroblastoma.
George RE; Sanda T; Hanna M; Fröhling S; Luther W 2nd; Zhang J; Ahn Y; Zhou W; London WB; McGrady P; Xue L; Zozulya S; Gregor VE; Webb TR; Gray NS; Gilliland DG; Diller L; Greulich H; Morris SW; Meyerson M; Look AT; Nature, 2008, vol. 455, issue 7215, p 975, ISSN 14764687. ISBN 14764687.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef